Dordaviprone

N/A

Report date: 2026/04/30 20:00:20
NMEFirst In Class

Base Information

Drug NameDordaviprone
Drug Alias NameTRAIL-inducing compound 10 (Oncoceutics)ModeysoNSC-350625TIC-10ONC-201 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCaseinolytic protease P activatorsDopamine D2 receptor antagonists
TargetsCaseinolytic protease PDopamine D2 receptor
Therapy Area/IndicationsSolid tumoursCentral Nervous System LymphomaDiffuse midline glioma +[24] 
Global Approved IndicationsDiffuse midline glioma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2025/08/06
Country/TerritoryCanadaUnited StatesSingapore +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOncoceutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesChimerix IncOncoceutics IncChina Resources Sanjiu Medical & Pharmaceutical Co Ltd +[8] 
Inactive CompaniesMasonic Cancer Center, University Of MinnesotaBrown UniversityUniversity Of Wisconsin-Madison +[4] 
Active IndicationsDiffuse midline gliomaMyelodysplastic SyndromesNeoplasm Metastasis +[14] 
Inactive IndicationsSolid tumoursCentral Nervous System LymphomaThalamic Diseases +[10] 

Other Information

ATC CodeN/A
Related LinksDrugBank